12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xenical orlistat regulatory update

EMA's CHMP concluded that the benefits of orlistat-containing medicines for obesity outweigh the potential risks of severe liver injuries. The committee found no strong evidence that orlistat increased the risk of severe liver injury. CHMP also said there was no known mechanism by which orlistat was expected to cause liver disorders. The committee concluded the number of reported...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >